NCT06957327进行中（未招募）1 期
A Phase 1b/2 Study of ERAS-601 SHP2 Inhibitor as a Monotherapy in Patients With Advanced and Progressing Chordoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 12
- 试验地点
- 14
- 主要终点
- Clinical Benefit Rate (Phase Ib)
研究概览
简要总结
The researchers are doing this study is to find out whether ERAS-601 is a safe and effective treatment that causes few or mild side effects in people with advanced and progressing chordoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years.
- •Have histologically confirmed chordoma that is not dedifferentiated or poorly differentiated subtype.
- •Have progressive disease per RECIST 1.1 defined by +20% change between any two scans in the 9 months prior to enrollment.
- •Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1
- •Recovered from acute, clinically significant toxicities associated with current/recent treatments to acceptable baseline status
- •Screening laboratory values must meet the following criteria and should be obtained within 30 days prior to study treatment:
- •Absolute neutrophil count (ANC) ≥ 1.5 x 103/m
- •Platelet count ≥ 75 × 103/mL without symptomatic bleeding
- •Hemoglobin > 9 g/dL
- •Serum electrolytes (sodium, potassium, magnesium, phosphorus, calcium) Grade ≤1 or within the institutional ranges of normal. If clinically appropriate, electrolytes may be corrected, and values reassessed prior to enrollment.
- •AST and ALT ≤ 2.5 × ULN or ≤ 5 × ULN for patients with liver metastases
- •Total bilirubin ≤ 1.5 × ULN (except in patients with Gilbert Syndrome who can have total bilirubin < 3.0 mg/dL)
- •Serum creatinine clearance <1.5 times ULN or ≥ 50 mL/min as determined by Cockcroft-Gault (Appendix 7) (creatinine clearance need not be calculated if serum creatinine is within normal limits).
- •Female patients of childbearing potential must have a negative serum beta-human chorionic gonadotropin pregnancy test within 7 days prior to receiving the first dose of study medication.
- •Female patients of childbearing potential must be willing to use an adequate method of contraception, as outlined in the protocol, for the course of the study through 120 days after last dose of study medication.
- •Male patients of childbearing potential must agree to use an adequate method of contraception, as outlined in the protocol, starting with the first dose of study therapy through 120 days after the last dose of study therapy.
- •Willing to comply with all protocol required- visits, assessments, and procedures.
- •Willing to participate in patient interviews for quality-of-life assessment and complete patient reported outcomes (PRO) questionnaires
- •Non-English speaking patients will not be required to complete patient reported outcomes.
排除标准
- •Previous treatment with a SHP2 inhibitor.
- •Documented PTPN11 mutations.
- •Is currently receiving another treatment within 4 weeks of the first dose of ERAS-601 that may impact the outcome of this trial.
- •Patients with prior antineoplastic therapy within <21 days or 5 half-lives, whichever is shorter.
- •Received radiation within 14 days of Cycle 1, Day
- •Received strong inhibitors or inducers of CYP3A4, including grapefruit, grapefruit juice, and herbal supplements from 7 days prior to the administration of study drug.
- •History of calcium and phosphate homeostasis disorder or systemic mineral imbalance with ectopic soft tissue calcification.
- •Gastrointestinal dysfunction that may affect drug absorption.
- •Have an untreated, uncontrolled, active infection (bacterial, fungal, or viral) requiring treatment that will impact this protocol.
- •History or current evidence of retinal pigment epithelial detachment (RPED), central serous retinopathy, retinal vein occlusion (RVO), or predisposing factors to RPED or RVO.
- •Sight-limiting degenerative corneal opacity.
- •Have any underlying medical condition (e.g. cardiac, pulmonary, hepatic, etc.), psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise patient safety and/or efficacy evaluation as per protocol.
- •Incomplete recovery or ongoing complications from prior surgery that in the opinion of the principal investigator will compromise safety of patient and/or efficacy evaluation of protocol.
- •Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of study therapy.
- •Have a second malignancy that is active and in the opinion of the principal investigator will compromise safety of patient and/or efficacy evaluation of protocol.
研究组 & 干预措施
ERAS-601
Experimental
All patients on the single-arm Phase 1b study will take ERAS-601 40mg BID, 3-weeks on 1-week off (3/1), as monotherapy. Each treatment cycle consists of a 4-week (28-day) treatment period.
干预措施: ERAS-601 (Drug)
结局指标
主要结局
Clinical Benefit Rate (Phase Ib)
时间窗: 1 year
proportion of patients with CR or PR at any time or SD ≥ 6 months per RECIST 1.1)
次要结局
未报告次要终点
研究者
研究点 (14)
Loading locations...
相似试验
尚未招募
2 期
A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic SyndromesMyelodysplastic SyndromesMDSBone Marrow DiseaseAnemiaNCT06594965Hansoh BioMedical R&D Company176
进行中（未招募）
1 期
A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT05781048Jiangsu HengRui Medicine Co., Ltd.56
已完成
2 期
A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic CoughRefractory Chronic CoughNCT05733533Guangdong Hengrui Pharmaceutical Co., Ltd97
Unknown
1 期
Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid TumorsSolid TumorNCT04588324Chinese PLA General Hospital50
终止
2 期
Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic LymphomaSLLChronic Lymphocytic LeukemiaCLLNCT02046928Ångstrom Pharmaceuticals5